Notice of fundraising

2025/03/26

PeptiStar Inc. (Head office: Settsu City, Osaka; President: Shinichiro Fujiie; hereinafter
‘PeptiStar’) is pleased to announce that it has completed a third-party allotment of new
shares to Shimadzu Corporation. 

PeptiStar was established in 2017, and it is a CDMO for peptides, nucleic acids and PDC*
APIs that supports the CMC of clinical and commercial APIs by strategically integrating
various cutting-edge technologies in Japan and promoting efficiency in the supply chain,
which is a bottleneck in research and development.  

Shimadzu Corporation, recognizing the pharmaceutical market as one of its most
strategic and important business segments, has been actively engaged in the
development and provision of comprehensive total solutions tailored to this field.
As part of a collaborative research initiative with our company, we successfully launched
a user-friendly oligonucleotide sequence analysis software in June 2023.

This third-party allotment of shares will enable us to further strengthen our product
portfolio and solution offerings through the development of innovative products and
technologies.Through these efforts, we are committed to contributing to the rapid
development and stable manufacturing pharmaceuticals.

 *Peptide Drug Conjugate